Forte Biosciences, Inc. — Director's Dealing 2017

Apr 12, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Tocagen Inc (TOCA)
CIK: 0001419041
Period of Report: 2017-04-12

Reporting Person: Kunkel Lori Anne (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (right to buy)	$14.77	2025-09-01	Common Stock (18115)		Direct
Stock Option (right to buy)	$14.98	2026-06-09	Common Stock (2644)		Direct

Footnotes

F1: 1/4th of the shares vest one year after 9/15/2015; 1/48th of the shares vest monthly thereafter over the next 3 years.

F2: 1/4th of the shares vest one year after 4/1/2016; 1/48th of the shares vest monthly thereafter over the next 3 years.